Interview with Derek Williams, Vice President and General Manager, Vifor Pharma…
You joined Vifor Pharma to establish a new structure in the UK. It is quite difficult to set up a new enterprise—what have been the main challenges for yourself and…
Address: The Old Stables, Bagshot Park, Bagshot, Surrey GU19 5PJ, United Kingdom
Tel: +44 (0) 1276 853 600
Web: http://www.viforpharma.com/en/
Vifor Pharma UK is an affiliate of the Vifor Pharma, the pharma business sector of the Galenica Group. Vifor Pharma, the Pharma business sector of the Galenica Group, is an internationally active company, which researches, develops, manufactures and markets pharmaceutical products worldwide. Galenica is a diversified group active throughout the healthcare market which among other things, develops manufactures and markets pharmaceutical products, runs pharmacies, provides logistical and database services and sets up networks.
Vifor Pharma UK focuses its activities on iron deficiency anaemia, a globally widespread ailment. It develops and manufactures iron replacement pharmaceutical products. These products are:
• Ferinject
• Venofer
You joined Vifor Pharma to establish a new structure in the UK. It is quite difficult to set up a new enterprise—what have been the main challenges for yourself and…
Liam O’Toole, CEO of Arthritis Research UK, discusses how arthritis impacts the British economy, raising public awareness of the condition, the potential ramifications of Brexit, and the importance of inter-stakeholder…
Mark Hicken, managing director of the UK and Ireland operations of Janssen, the pharmaceutical arm of Johnson & Johnson, highlights the company’s long-standing R&D presence in the UK. He calls…
Sir Robert Lechler, president of the Academy of Medical Sciences (AMS), discusses the Academy’s role in promoting medical research in the UK and how that stands to change in the…
Keith Thompson, CEO of the Cell & Gene Therapy Catapult, one of a number of Catapult institutions in the UK designed to help commercialize innovative research, discusses strategy, funding, international…
Terry O’Regan, VP and managing director at Biogen UK and Ireland, discusses the company’s longstanding commitment to the UK, market access issues, and why Biogen is staying the course with…
Sir John Savill, chief executive of the Medical Research Council between 2010 and 2018, discusses the organization’s transition into part of the new UK Research and Innovation (UKRI) grouping, the…
Steve Ford, CEO of Parkinson’s UK, one of the UK’s leading research-based charities, discusses his organization’s recent Digital Leadership Award, presenting the needs of Parkinson’s patients to stakeholders, and why…
Tony Jones, CEO of One Nucleus, a life sciences membership organization centered on the Greater London-Cambridge-East of England corridor, discusses the role of SMEs within the UK’s healthcare ecosystem, translational…
Lord O’Shaughnessy, parliamentary under secretary of state for health in the UK, discusses how stakeholders are interacting to ensure that the UK remains at the forefront of the global life…
Ben Ellis, general manager at Lupin UK and Ireland, talks about the strategic challenges of transitioning from the sphere of generics to specialist pharma and how he hopes Lupin can…
Sir John Chisholm, executive chair of Genomics England – a company set up and owned by the UK Department of Health to run the 100,000 Genomes Project, which aims to…
Aisling Burnand, CEO of the Association of Medical Research Charities (AMRC), shares the organization’s vision and the significant contributions of its member charities to the life sciences R&D ecosystem in…
See our Cookie Privacy Policy Here
